The inactivation of eggs of helminthes under the action of narrowband ultraviolet radiation of excilamps

The inactivation of eggs of Opisthorchis felineus and Diphyllobothrium latum in the water under the action of UV excilamps at 222 and 282 nm in dependence on the surface dose of radiation was studied. It was observed that the water disinfection from eggs of helminthes was more efficient at 222 nm, than at 282 nm. At the surface dose up to 5 mJ/cm2 of UV radiation at 222 nm up to 85 % of Opisthorchis felineus eggs were inactivated. At the comparable surface dose of UV radiation at 222 nm up to 56 % of Diphyllobothrium latum eggs were inactivated

The possibilities of impulse oscillometry in the diagnosis of the lung function disorders after COVID-19

Background. Impulse oscillometry (IOS) is an effort independent method of studying lung mechanics. Aim. To study the diagnostic significance of IOS in assessing lung mechanics after COVID-19. Materials and methods. Spirometry, body plethysmography, diffusion test (DLco), IOS parameters were analyzed in 315 patients (the median age 48 years), the median period from the beginning of COVID-19 to the study was 50 days. Statistical analysis included descriptive statistics, correlation analysis and one-dimensional logistic regression analysis with an assessment of odds ratios. Results. In general group, spirometry and body plethysmography parameters were in normal values, while DLCO was reduced in 61% of patients. Parameters of IOS were analyzed in the general group and between the groups, depending on the value of DLco and total lung capacity (TLC): normal or reduced. In general group, reactance area (AX), hererogeneity of resistance Rrs5–Rrs20, resistance at 5 Hz (Rrs5), reactance at 5 Hz (ΔXrs5) were increased in 29.8%, 17.8%, 6%, 4.8% of patients, respectively, and were statistically significantly higher in the group with reduced TLC, whereas in the group with reduced DLco AX, Rrs5–Rrs20 were statistically significantly higher. Logistic regression analysis showed that patients with Rrs5-Rrs200.07 kPa×sec/l or AX0.32 kPa/l had a 1.99-fold and 2.24-fold increased risk for decrease DLco, respectively, while the risk of decrease in TLC was 2.25-fold (p=0.012) and 3.16-fold (p0.001) higher, respectively. Conclusion. IOS allow to detect both dysfunction of small airways (if AX or Rrs5–Rrs20 are increased) and the risk of restrictive pattern and lung diffusion impairment after COVID-19

Risk factors for adverse outcomes in elderly patients with asthma and severe COVID-19 at the hospital and early post-hospital stages

Background. Mortality and COVID-19 related factors are thoroughly analyzed. Given the large number of hospitalized patients, the potential short- and long-term COVID-19 related complications, further research is needed on the possible consequences of hospitalization, especially in higher-risk patients, after prolonged hospitalization and intensive care admission. Aim. To study the clinical course and outcomes of severe COVID-19 in elderly patients with asthma at the hospital and early post-hospital stages. Materials and methods. The study included 131 elderly patients (WHO, 2020) 60 years old, n=131 with asthma, hospitalized for severe COVID-19. Of these, 86 (65.6%) patients survived, 30 (22.9%) died in the hospital, and 15 (14.9%) patients died after discharge from the hospital (in the 90-day post-hospital period). COVID-19 was confirmed by laboratory tests (SARS-CoV-2 PCR RNA test) and/or clinically and radiologically. All patients had a documented history of asthma. Patients were followed up during the hospital stay and for 90 days after discharge. Results. Comparison of outcomes showed that in the groups of patients with a fatal outcome (regardless of the stage), the Charlson comorbidity index, respiratory rate, extent of lung damage assessed by computed tomography, the absolute leukocyte and neutrophil number and the ratio of neutrophils to lymphocytes were statistically significantly higher. The absolute number of eosinophils was lower in these groups. In the group of patients who died during hospitalization, severe (IVV) asthma (p=0.03), steroid use during the previous year (p=0.02), chronic heart failure with a reduced ejection fraction (p=0.009) were more common, and atopic asthma phenotype was less common (p=0.02). In those who died after discharge, more common were non-invasive ventilation and diabetes mellitus (p0.001). The multivariate regression analysis model revealed the most significant predictors of mortality at the hospital and early post-hospital stages. Conclusion. Adverse outcomes of severe COVID-19 in elderly patients with asthma include hospital and post-hospital mortality. The most significant predictors of mortality are the comorbidity index and low eosinophil count. Hospital mortality is associated with a higher ratio of neutrophils to lymphocytes and lower total protein levels; early (90-day) post-hospital mortality is associated with extensive lung damage shown by computed tomography and diabetes mellitus

Prognostic Value of Melatonin in Patients with Chronic Obstructive Pulmonary Disease

The article outlines a detailed examination of multiple scientific studies investigating how melatonin affects COPD's advancement and growth. The severity of oxidative stress in COPD, a complex disease with multiple factors, is significantly reduced by melatonin by activating intracellular antioxidants, as suggested by the data acquired. Considering the available data, we can conclude that melatonin has a protective role against oxidative stress in COPD patients in addition to regulating the circadian rhythm

Some Aspects of Mast Cells Carboxypeptidase A3 Participation in the Pathogenesis of COVID-19

Background: This study aimed to determine the involvement of carboxypeptidase A3 (CPA3) in developing lung damage in patients with COVID-19. Methods and Results: The study included samples of autopsy material from the lungs of patients who died as a result of severe COVID-19 (the main group [MG] and persons who died from external causes (the control group [CG]). Immunohistochemical staining for CPA3 was carried out. A quantitative study of CPA3-positive mast cells (MCs) and the degree of their degranulation was carried out using a ×40 objective lens with an analysis of ≥50 fields of view with further conversion to 1 mm². Significant representation of CPA3-positive MCs per 1 mm2 of CPA3-positive MCs, CPA3-positive MCs with signs of degranulation (SD), and co-adjacent MCs was found in the MG compared to the CG (P=0.01 in all cases). In the main group, positive correlations were identified between the total number of CPA3-positive MCs, CPA3-positive MCs with SD and the blood hemoglobin level shortly before death (r=0.491 [P=0.008] and r=0.521 [P=0.004], respectively). Co-adjacent CPA3-positive MCs were negatively correlated with blood eosinophils at the beginning of hospitalization (r=-0.420 [P=0.023]). Also, the number of separately lying, CPA3-positive MCs negatively correlated with the blood monocyte shortly before death (r=-0.384 [P=0.044]). A positive correlation was established between the total number of CPA3-positive MCs, CPA3-positive MCs with SD, and adjacent CPA3-positive MCs with total blood protein in patients at the beginning of hospitalization (r=0.431 [P=0.020], r=0.449 [P=0.015] and r=0.456 [P=0.013], respectively). In addition, the study demonstrated a positive correlation between CPA3-positive MCs with SD and the total number of CPA3-positive MCs with blood aPTT levels (r=0.304 [P=0.045] and r=0.375 [P=0.045], respectively). A negative correlation was also found between the total number of CPA3-positive MCs and the blood INR level (r=-0.812 [P=0.050]). Finally, in patients at the beginning of hospitalization, a negative correlation was found between CPA3-positive MCs with SD, CPA3-positive MCs without SD, separately located CPA3-positive MCs, adjacent CPA3-positive MCs, and the total number of CPA3-positive MCs with blood amylase (r=-0.550 [P=0.002], r=-0.452 [P=0.045], r=-0.485 [P=0.030], r=-0.622 [P=0.008], and r=-0.590 [P=0.006], respectively). Conclusion: Our study identifies the potential involvement of CPA3 in the pathogenesis of severe COVID-19. However, many aspects of its participation remain unclear and require further study

Practical recommendations for choosing an immunobiological preparation for the treatment of severe bronchial asthma of T2-endotype

Biological therapy of bronchial asthma (BA) is a modern method of treating severe forms of the disease, that are uncontrolled by traditional pharmacotherapeutic approaches. Currently, 5 monoclonal antibody (AT) preparations are registered in the world for the treatment of severe bronchial asthma (SBA) of the T2 endotype (T2-SBA) – antibodies, binding to immunoglobulin (Ig) E (anti-IgE – omalizumab), interleukin antagonists (IL)-5 (anti-IL-5 – mepolizumab, resizumab) and its receptor (anti-IL-5Rα – benralizumab), as well as antibodies, that selectively bind to the IL-4 and -13 receptor (anti-IL-4 /13Rα – dupilumab). The article presents data on the effectiveness of these drugs in relation to the key characteristics of SBA, formulates clinical and laboratory criteria, the study of which in real practice can potentially predict the likelihood of a clinical response to a particular type of biological therapy. An algorithm is proposed for choosing a targeted therapy strategy for patients with SBA, clinically associated with allergies, for patients with severe non-allergic eosinophilic BA and for patients with eosinophilic BA of a combined phenotype.Биологическая терапия бронхиальной астмы (БА) представляет собой современный метод лечения тяжелых форм заболевания, неконтролируемых при помощи традиционных фармакотерапевтических подходамов. В настоящее время в мире зарегистрированы 5 препаратов моноклональных антител (АТ) для лечения тяжелой бронхиальной астмы (ТБА) Т2-эндотипа (Т2-ТБА) – АТ, связывающие иммуноглобулин (Ig) Е (анти-IgE – омализумаб), антагонисты интерлейкина (IL)-5 (анти-IL-5 – меполизумаб, реслизумаб) и его рецептора (анти-IL-5Rα – бенрализумаб), а также АТ, избирательно связывающиеся с рецептором IL-4 и -13 (анти-IL-4/13Rα – дупилумаб). В статье приведены данные об эффективности указанных препаратов в отношении ключевых характеристик ТБА, сформулированы клинико-лабораторные критерии, при исследовании которых в реальной практике потенциально может быть предсказана вероятность клинического ответа на тот или иной вид биологической терапии. Предложен алгоритм выбора стратегии таргетной терапии для пациентов с ТБА, клинически ассоциированной с аллергией, для больных тяжелой неаллергической эозинофильной БА и для страдающих эозинофильной БА сочетанного фенотип